about
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisA critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistanceDistinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerPhosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomasIn Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.Approaches to identifying synthetic lethal interactions in cancer.Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patientsLoss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesisOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.The two faces of FBW7 in cancer drug resistance.The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapyA comprehensive survey of the mutagenic impact of common cancer cytotoxicsIncreased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistanceBRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.Systemic therapy options in BRCA mutation-associated breast cancer.Links between genome integrity and BRCA1 tumor suppression.MicroRNAs and DNA damage response: implications for cancer therapy.Targeting homologous recombination-mediated DNA repair in cancer.MicroRNAs: master regulators of drug resistance, stemness, and metastasis.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.Just like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutationsMolecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time.BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Current status of poly(ADP-ribose) polymerase inhibitors and future directions.Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.The Novel Pathogenic Mutation c.849dupT in Contributes to the Nonsense-Mediated mRNA Decay of in Familial Breast Cancer
P2860
Q26766285-C1F3389C-2A08-493D-9644-71D07B57E7A4Q26852274-8FAD73EF-7CF7-453F-BD5D-4C48B26FFCF4Q26865888-BC493136-F9C0-4A1A-85C3-9CBFD8EBE22AQ28543175-6D3F7473-E07F-4A1C-AF5A-06A6E02635CCQ33704050-36D0C0EE-3DB0-4371-B0DF-1A80D012B584Q33917649-67E2FD01-A56C-4711-8465-873D88E7236EQ34248336-EC912E13-B574-455A-B28D-7627C3B24DABQ35018746-44721D9F-5A26-4D86-9F5D-CD3AF9242999Q35050560-41086239-5BF9-4749-A672-FAC131493CD9Q35060446-01D8ABCF-193B-4A78-A95F-50A2A958FC64Q35440379-7718A632-359A-4CC5-9F0B-19E9910B3E1DQ35647469-36F77700-CD64-49E2-B3E0-29964FAC5E82Q35744147-CDA33FF3-8744-471E-A292-7485CB36ADBAQ35828551-49EB1379-F3D9-4369-968F-52F1F02DE9BDQ35837949-7E3C5C34-3132-4A00-8351-04A3C532E235Q35999467-4E7D2A70-9A11-40C9-8948-1C15A4FE5C48Q36689932-A64AF1BF-76D5-4247-AC7B-967457395759Q36886849-909FEC7F-ECD9-422E-8A0A-B7A3F2EDC09FQ36933976-A9121D2A-86BA-4FBA-BC3F-B84FE0FD0826Q37299652-5832C443-2DDA-4B7F-84DA-FC9462A8E6ADQ37605747-13BFF8A0-E0D4-4F30-8EB9-4B29318553B0Q37607283-DBA6A93A-427F-45BB-ACF0-1E3D68AC0086Q37644990-A57A489A-D472-48F3-BCC4-85FCE0FC97B4Q38025991-E727D838-65DE-4BA5-963E-378B9EB50E3CQ38029897-2968BFF5-9524-465F-876A-32AF21C33C88Q38068797-2835A884-C71D-40B7-A677-8FD475B68726Q38184667-D8EA346E-FE3B-49AE-BFD3-C140F6D774F6Q38186568-AFBD3E6A-19F5-47BE-BF80-E662DA3C868EQ39113994-8F2CDF7A-1C89-4CF0-837A-EAEF01A958CCQ42236265-6FE86572-498A-4E96-AEA0-4A8BD2712708Q43158474-4E2386E2-266E-4F5A-A6D1-B5AF77F9AF77Q46204355-8F191B90-D030-4114-AA25-638FD57CAD3CQ46354502-E0091E9B-B88D-4C3D-85AB-66A79E83FE79Q47155297-6619A096-F739-49B9-94E5-328B34E5F50EQ52586080-D958919A-95E9-4843-836A-6A0EAC17A9BAQ53730678-25310737-C7A3-4527-B49B-73A46CE5A564Q55159440-770F0E98-EFF0-4AAE-B16A-D80D945D6DCCQ57124701-0FC02E23-FD84-4253-B39E-E1940D00007C
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Secondary mutations of BRCA1/2 and drug resistance
@ast
Secondary mutations of BRCA1/2 and drug resistance
@en
Secondary mutations of BRCA1/2 and drug resistance
@nl
type
label
Secondary mutations of BRCA1/2 and drug resistance
@ast
Secondary mutations of BRCA1/2 and drug resistance
@en
Secondary mutations of BRCA1/2 and drug resistance
@nl
prefLabel
Secondary mutations of BRCA1/2 and drug resistance
@ast
Secondary mutations of BRCA1/2 and drug resistance
@en
Secondary mutations of BRCA1/2 and drug resistance
@nl
P2860
P1433
P1476
Secondary mutations of BRCA1/2 and drug resistance
@en
P2093
Elizabeth M Swisher
Kiranjit K Dhillon
P2860
P304
P356
10.1111/J.1349-7006.2010.01840.X
P577
2011-01-30T00:00:00Z